In conclusion, we have shown proof-of-concept for a genetically programmable vaccine based on the in situ production of antigens from DNA templates. Further immunization studies focusing on co-administering of DNAs, encoding biologically relevant antigens and genetic adjuvants (e.g. cytokines) are needed to demonstrate the possibilities and limits of the AnExIL vaccination platform.